Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine‑tolerance molecular markers following 18 years of artemisinin‑based combination therapy use in Mpumalanga Province, South Africa (2001–2018)

Show simple item record

dc.contributor.author Raman, Jaishree
dc.contributor.author Kagoro, Frank M.
dc.contributor.author Mabuza, Aaron
dc.contributor.author Malatje, Gillian
dc.contributor.author Reid, Anthony
dc.contributor.author Barnes, Karen I.
dc.date.accessioned 2019-11-27T08:52:03Z
dc.date.available 2019-11-27T08:52:03Z
dc.date.issued 2019-08-22
dc.description.abstract BACKGROUND : The ability of Plasmodium falciparum parasites to develop resistance to widely used anti-malarials threatens malaria control and elimination efforts. Regular drug efficacy monitoring is essential for ensuring effective treatment policies. In low transmission settings where therapeutic efficacy studies are often not feasible, routine surveillance for molecular markers associated with anti-malarial resistance provides an alternative for the early detection of emerging resistance. Such a longitudinal survey of changes in the prevalence of selected molecular markers of resistance was conducted in the malaria-endemic regions of Mpumalanga Province, South Africa, where malaria elimination at a district-level is being pursued. METHODS : Molecular analyses to determine the prevalence of alleles associated with resistance to lumefantrine (mdr86N, crt76K and mdr1 copy number variation) and sulfadoxine–pyrimethamine (dhfr triple, dhps double, SP quintuple) were conducted between 2001 and 2018, while artemisinin resistance markers (kelch13 mutations) were assessed only in 2018. RESULTS : Parasite DNA was successfully amplified from 1667/2393 (70%) of malaria-positive rapid diagnostic tests routinely collected at primary health care facilities. No artemisinin resistance-associated kelch13 mutations nor amplification of the mdr1 gene copy number associated with lumefantrine resistance were observed. However, prevalence of both the mdr86N and crt76K alleles increased markedly over the study period, with all isolates collected in 2018 carrying these markers. SP quintuple mutation prevalence increased steadily from 14% in 2001 to 96% in 2018. Mixed alleles at any of the codons assessed were rare by 2018. CONCLUSION : No kelch13 mutations confirmed or suspected to be associated with artemisinin resistance were identified in 2018. Although parasites carrying the mdr86N and crt76K alleles associated with reduced lumefantrine susceptibility were strongly selected for over the study period, nearing fixation by 2018, the marker for lumefantrine resistance, namely increased mdr1 copy number, was not observed in this study. The increase in mdr86N and crt76K en_ZA
dc.description.department School of Health Systems and Public Health (SHSPH) en_ZA
dc.description.librarian am2019 en_ZA
dc.description.sponsorship The SAMRC, the NICD the WHO/TDR, GMP and WHO/AFRO. en_ZA
dc.description.uri http://www.malariajournal.com en_ZA
dc.identifier.citation Raman, J., Kagoro, F.M., Mabuza, A. et al. 2019, 'Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine‑tolerance molecular markers following 18 years of artemisinin‑based combination therapy use in Mpumalanga Province, South Africa (2001–2018)', Malaria Journal. vol.18, art. 280, pp. 1-12. en_ZA
dc.identifier.issn 1475-2875
dc.identifier.other 10.1186/s12936-019-2911-y
dc.identifier.uri http://hdl.handle.net/2263/72406
dc.language.iso en en_ZA
dc.publisher BioMed Central en_ZA
dc.rights © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License. en_ZA
dc.subject Resistance en_ZA
dc.subject Kelch13 en_ZA
dc.subject Malaria en_ZA
dc.subject Plasmodium falciparum en_ZA
dc.subject Mutations en_ZA
dc.subject Mpumalanga province, South Africa en_ZA
dc.subject Artemisinin-based combination therapy (ACT) en_ZA
dc.subject Dihydropteroate synthetase (dhps) en_ZA
dc.subject Codon 86 of the P. falciparum multi-drug resistance gene 1 (mdr186) en_ZA
dc.subject Codon 76 of the P. falciparum chloroquine resistance transporter gene (crt76) en_ZA
dc.subject Efficacy en_ZA
dc.subject Mutations en_ZA
dc.subject Surveillance en_ZA
dc.subject Polymorphism en_ZA
dc.subject Identification en_ZA
dc.subject Implementation en_ZA
dc.subject Polymerase chain reaction (PCR) en_ZA
dc.subject Drug resistance en_ZA
dc.subject Sulfadoxine-pyrimethamine en_ZA
dc.title Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine‑tolerance molecular markers following 18 years of artemisinin‑based combination therapy use in Mpumalanga Province, South Africa (2001–2018) en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record